39 listed companies disclosed their 2022 annual report performance forecasts, focusing on electronics, medicine and other fields

【Pharmaceutical Network Industry News】According to the statistics of the Oriental Wealth Network Data Center, up to now, 39 listed companies have disclosed the performance forecast of the 2022 annual report, mainly focusing on electronics, medicine, technology and other fields
.
Among them, in the pharmaceutical industry, at least 5 listed companies have issued annual performance forecasts, including Dongxing Medical, Jardine Jardine Jiaye, Xintiandi, Huaxia Ophthalmology, Hongbo Pharmaceutical, etc
.
Overall, the annual performance of pharmaceutical companies in 2022 is good
.
39 listed companies disclosed 2022 annual report performance forecasts, focusing on electronics, medicine and other fields (Image source: Pharmaceutical Network) Dongxing Medical: net profit increased by 8.
04% to 17.
04% year-on-year Dongxing Medical announced on November 10 that it expects operating income from January to December 2022 to be 485 million yuan to 515 million yuan, an increase of 8.
62% to 15.
34% over the previous year; The net profit was 120 million yuan to 130 million yuan, an increase of 8.
04% to 17.
04%
over the previous year.
As for the reasons for the increase in performance, the company said that the sales revenue of the company's stapler products in overseas markets increased, and the revenue of the stapler parts business increased compared with the previous year, resulting in an increase in the company's operating income and net profit compared with the previous year
。 Jardine Jardine Jardine Jiaye: net profit increased by 140.
85% year-on-year to 179.
67% Jardine Jardine announced on October 31 that it is expected that the operating income from January to December 2022 will be 1.
444 billion yuan to 1.
544 billion yuan, an increase of 117.
96% to 133.
06% over the previous year; The net profit attributable to shareholders of the listed company was 350 million yuan to 407 million yuan, an increase of 140.
85% to 179.
67%
over the previous year.
The company's net profit in the first three quarters also doubled year-on-year, mainly due to the continuous impact of competitor product recalls, the further increase in demand for the company's products in the US market, and the increase in orders; And the environment continued to stabilize, and the
sales of regular sales continued to grow.
Xintiandi: net profit increased by 11.
33% to 14.
8% year-on-year Xintiandi announced on November 15 that it is expected to have operating income of 620 million yuan to 670 million yuan from January to December 2022, an increase of 20.
66% to 30.
39% over the previous year; It is expected that the net profit attributable to shareholders of the listed company will be 128 million yuan to 132 million yuan, an increase of 11.
33% to 14.
8%
over the previous year.
The main reason for the increase in performance is that the company's industry has a good development trend, and the company's own contracts in hand are sufficient, which effectively ensures the sustained and rapid development
of the company's business performance.
It is understood that Xintiandi belongs to the API subdivision track, the company is an internationally competitive chiral pharmaceutical intermediate manufacturer, mainly engaged in the research and development, production and sales of chiral pharmaceutical intermediates, the main products are L-p-hydroxyphenylglycine series products and p-toluenesulfonic acid
.
The company has said that it is expected that in the future, with the increasing number of original drugs with patent expiration, the number of generic drugs will rise rapidly, and the market size of APIs will increase year by year, and the demand for corresponding pharmaceutical intermediates will be greatly increased
。 Huaxia Ophthalmology: net profit increased by 14.
31% to 23.
1% year-on-year Huaxia Ophthalmology announced on November 4 that it is expected to have operating income of 3.
317 billion yuan to 3.
44 billion yuan from January to December 2022, an increase of 8.
24% to 12.
26% over the previous year; The net profit attributable to shareholders of the listed company was 520 million yuan to 560 million yuan, an increase of 14.
31% to 23.
1%
over the previous year.
The company also achieved double growth in revenue and net profit in the first three quarters, when the company said that the main reason was that on the one hand, the company continued to provide comprehensive basic diagnosis and treatment services for the public while conforming to the trend of medical and consumption upgrading, actively improving the quality and added value of ophthalmic medical services, and providing differentiated services according to the actual needs of patients; On the other hand, vigorously develop non-medical insurance projects such as refractive energy, and continue to enrich the company's business structure
.
Hongbo Pharmaceutical: net profit fell 4.
86% year-on-year to 23.
89% Hongbo Pharma announced on the evening of October 31 that it expects operating income from January to December 2022 to be 447 million yuan to 548 million yuan, a year-on-year change of -0.
27% to 22.
26%; It is expected that the net profit attributable to shareholders of the listed company will be 56 million yuan to 70 million yuan, down 4.
86% to 23.
89%
from the previous year.
As for the reasons for the change in performance, the company said that mainly due to the environment, the management expenses increased significantly in the second quarter of 2022, and secondly, the company's fixed costs increased more
than in the same period.
In addition, the company will increase R&D investment in a number of technology platforms in 2022, and it is expected that this year's R&D investment will also increase
significantly compared with last year.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.